Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting : lessons from the ANTARCTIC trial by Messas, Nathan et al.
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(5):E440-E443jtd.amegroups.com
The recently reported ANTARCTIC trial by Cayla and 
colleagues is the latest large-scale study of personalized 
antiplatelet therapy based on platelet function testing (1). In 
this open-label, blinded end-point, randomized, controlled 
trial, the authors ascertained the net clinical benefit of 
individualized antiplatelet therapy based on platelet function 
monitoring in elderly patients undergoing stenting (PCI) 
for an acute coronary syndrome (ACS). Eight hundred 
and seventy-seven ACS patients aged over 75 years were 
randomly assigned to receive either prasugrel 5 mg daily 
with no monitoring or treatment adjustment (conventional 
group, n=442) or the same starting agent, but with the 
possibility to tailor antiplatelet therapy either through 
dose titration or switching to an alternative P2Y12 receptor 
inhibitor in case of inadequate platelet response (monitoring 
group, n=435). In the monitoring group, platelet function 
testing was assessed using the VerifyNowTM assay 
14 days post-PCI and repeated 14 days later in patients 
who required therapy adjustment. High platelet reactivity 
(HPR) and low platelet reactivity (LPR) to adenosine 
diphosphate (ADP) were defined as >208 and <85 PRU, 
respectively. The dose of prasugrel was escalated from 5 to 
10 mg daily in patients with HPR, or therapy was switched 
to clopidogrel 75 mg per day in patients with LPR.
The findings from this well-designed trial in elderly 
patients with ACS (who represent a population at high risk 
for ischemic and bleeding events) too frequently excluded 
from clinical studies, can be summarized as follows: (I) the 
platelet function testing guided-therapy approach resulted 
in treatment intensification for 4% of patients (16/435) and 
de-escalation of antiplatelet regimen for 39% (171/435) 
of patients in the monitoring group; (II) at 12 months, 
the primary composite end-point of cardiovascular death, 
myocardial infarction, stroke, definite stent thrombosis, 
urgent revascularization or bleeding, occurred in 120 (28%) 
patients in the monitoring group compared with 123 (28%) 
patients in conventional group (P=0.98); (III) the main 
safety endpoint of major bleeding (BARC type 2, 3 or 5) 
occurred in about a fifth of patients in each group (P=0.77); 
and (IV) this lack of statistical differences between groups 
was consistent across all the individual components of both 
ischemic and bleeding endpoints.
The ANTARCTIC trial is the latest in a string of trials 
reporting disappointing results for tailored antiplatelet 
therapy based on platelet function monitoring. Indeed, 
the rationale for personalized antiplatelet therapy stems 
naturally from numerous pharmacodynamic studies which 
demonstrated a wide variability of response to P2Y12 
receptor inhibition in particular in patients treated by 
clopidogrel (2-4). Moreover, several reports suggested 
an association between HPR and post stenting ischemic 
events such as stent thrombosis or cardiovascular death (5), 
and a possible link between LPR and bleeding events 
in stented patients (6-8). Altogether, these observations 
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led to the concept of a therapeutic window for DAPT 
(i.e. ,  an “optimal” range of platelet reactivity) to 
improve outcomes,  with the added complexity of 
defining standardized threshold values for HPR and 
LPR according to the type of platelet function assay 
used (9). However, so far studies on the potential of 
platelet function testing to improve outcomes in HPR 
patients undergoing PCI have yielded conflicting results 
in cohort studies and in randomized trials. Although 
promising results from smaller studies were reported (10), 
large-scale randomized, controlled trials consistently 
failed to establish any difference in cardiovascular 
outcomes between a conventional  strategy and a 
platelet function monitoring-guided approach (Table 1). 
Some considerations help to position the ANTARCTIC 
trial results in the current landscape of platelet function-
based tailoring of antiplatelet therapy.
Previous studies have been criticized for enrolling 
low-risk patients whose rates of outcomes did not allow 
much differentiation between the standard-of-care and 
the adjusted treatment arms, as were the case in the 
GRAVITAS and the TRIGGER-PCI studies (11,12). In 
contrast, the ANTARCTIC trial targeted a higher risk 
population of patients, who indeed went on to have a 
higher rate of adverse events, but who nonetheless did not 
seem to benefit from tailored therapy.  It has also been 
suggested that the therapeutic adjustments attempted 
provided only marginally altered platelet inhibition (11). 
While the intensification arm of ANTARCTIC did use 
an effective increase in prasugrel dose, it only occurred 
in 4% of patients receiving 5 mg of prasugrel daily. This 
rate is significantly lower than would have been expected, 
Table 1 Randomized control trials assessing the utility of platelet function monitoring to reduce ischemic/bleeding outcomes in PCI patients
Studies GRAVITAS TRIGGER-PCI ARCTIC ANTARCTIC
Patients 
characteristics
~58% stable CAD 
~27% UA without MI 
~15% NSTE-ACS 
PCI with ≥ 1 DES
Stable CAD 
PCI with ≥1 DES
73% stable CAD 
27% NSTE-ACS 
PCI with DES




Number of patients n=2,800 n=423 n=2,440 n=877
Level of ischemic risk Low risk Low risk Low risk High risk
PFM method VerifyNowTM assay VerifyNowTM assay VerifyNowTM assay VerifyNowTM assay
PFM cutoff HPR: ≥230 PRU HPR: >208 PRU HPR: ≥235 PRU or ≤15% inhibition HPR: ≥208 PRU 
LPR: ≤85 PRU
Timing PFM 12 to 24 h after PCI 2 to 7 h after the first 
clopidogrel 75 mg 
maintenance dose the 
morning after PCI
Before PCI stenting 
Control PFM 2 to 4 weeks after PCI
Day 14 after PCI 
Control PFM 14 days after 1st test
Treatment in the PFM 
group
Clopidogrel 600 mg 
loading dose, followed 
by 150 mg maintenance 
dose
Clopidogrel 600 mg 
loading dose, followed by 
prasugrel 10 mg daily
Clopidogrel 600 mg loading dose, 
followed by clopidogrel 150 mg daily 
(~90%) or prasugrel 10 mg daily 
(~10%)
Prasugrel 5 mg daily (55%); prasugrel 
10 mg (4%); clopidogrel 75 mg (39%)
Primary efficacy  
end-point
6-month cardiovascular 
death, nonfatal MI, or 
stent thrombosis: 2.3% 
vs. 2.3%; HR 1.01, 
P=0.97
6-month cardiovascular 
death or myocardial 
infarction: 0% vs. 0.5%; 
P=NE
1-year death, MI (including 
periprocedural increase in cardiac 
biomarkers), stent thrombosis, 
stroke, or urgent revascularization: 
34.6% vs. 31.1%; HR 1.13, P=0.10
1-year cardiovascular death, MI, 
stroke, stent thrombosis, urgent 
revascularization, and BARC-defined 
bleeding (types 2, 3, or 5): 28% vs. 
28%; HR 1.0, P=0.98
Bleeding outcomes Severe or moderate 
GUSTO bleeding: 1.4% 
vs. 2.3%; HR, 0.59, 
P=0.10
Non-CABG major TIMI 
bleeding: 1.4% vs. 0.5%; 
P=NE
Major STEEPLE bleeding: 2.3% vs. 
3.3%; HR 0.57, P=0.12
BARC-defined bleeding (types 2, 3, 
or 5): 21% vs. 20%; HR 1.04, P=0.77
CAD, coronary artery disease; UA, unstable angina; NSTE-ACS, non–ST-segment elevation-acute coronary syndrome; MI, myocardial 
infarction; DES, drug-eluting stent; NE, not evaluated due to insufficient data; PCI, percutaneous coronary intervention; PFM, platelet 
function monitoring; HPR, high platelet reactivity; LPR, low platelet reactivity.
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given that the GENERATIONS trial that assessed 
platelet function on prasugrel 5 vs. 10 mg in very elderly 
stable CAD patients, found 14% of patients presenting 
with HPR, with a more stringent HPR definition (13). 
It is therefore not clear why the ANTARCTIC study 
population, which should have presented with higher 
platelet reactivity due to their ACS presentation (14), had 
such an important underrepresentation of HPR leading 
to intensification of treatment.  Other criticisms of prior 
trials included the fact that newer P2Y12 receptor inhibitors 
provide a significantly more predictable and profound 
inhibition of platelet function at the time of PCI than 
clopidogrel, advocating that these agents should be used 
at presentation to cover the HPR associated with ACS and 
PCI (11,12,15). The ANTARCTIC trial addressed this 
issue through homogeneous administration of prasugrel 
5 mg to all participants, with possible de-escalation to 
clopidogrel 75 mg daily in patients with LPR. However, 
recent studies in elderly patients have shown similar 
rates of bleeding complications between patients treated 
with prasugrel 5 mg and clopidogrel 75 mg (13,16), and 
therefore the failure to improve the prognosis of patients 
in the monitoring group in the ANTRACTIC study might 
reflect the similar bleeding risks associated with these drug 
regimens rather than the actual predictive value of platelet 
function monitoring.  The ongoing TROPICAL-ACS trial 
also includes a de-escalation arm based on platelet function 
monitoring, and should help shed light on this important 
issue (17). Finally, an important consideration that still 
plagues the field of personalized antiplatelet therapy, is 
the fact that all previous studies, including ANTARCTIC, 
investigated the question of a tailored antiplatelet therapy 
based on a single platelet function assay, the VerifyNowTM 
system (1,11,12,14). While the VerifyNowTM assay remains 
the most widely used and studied test for the link between 
HPR and clinical outcomes after PCI, other assays capture 
different aspects of platelet function and identify different 
patients as requiring antiplatelet therapy adjustment (18). 
Whether strategies based on alternative platelet function 
testing modalities would yield the same results remains an 
open debate, which the ongoing TROPICAL-ACS trial 
using the MultiplateTM technology may help to answer (17).
In summary, while the findings from the ANTARCTIC 
study are in line with previous trials of platelet function 
testing-driven personalization of antiplatelet therapy, there 
are still a number of open questions that require elucidation 
before recommendations for or against platelet function 
monitoring may be made. Moreover, it may be that a 
combination of clinical, genomic and pharmacodynamic 
variables will be necessary to provide the optimal patient 
profile to target personalized antiplatelet therapy. Ongoing 
research with alternative approaches to personalization is 
eagerly awaited.
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